Natera Stock (NASDAQ:NTRA)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$216.50

52W Range

$131.81 - $256.36

50D Avg

$206.46

200D Avg

$205.21

Market Cap

$31.40B

Avg Vol (3M)

$1.41M

Beta

1.54

Div Yield

-

NTRA Company Profile


Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.

Show More

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

4,424

IPO Date

Jul 01, 2015

Website

NTRA Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
Licensing and other$10.29M$11.84M$14.05M
Product$2.30B$1.69B$1.07B
Oncology products--$19.30M
Genetic testing services--$18.30M

Fiscal year ends in Dec 25 | Currency in USD

NTRA Financial Summary


Dec 25Dec 24Dec 23
Revenue$2.31B$1.70B$1.08B
Operating Income$-309.91M$-222.29M$-446.25M
Net Income$-208.16M$-190.43M$-434.80M
EBITDA$-264.02M$-148.08M$-383.28M
Basic EPS$-1.52$-1.53$-3.78
Diluted EPS$-1.52$-1.53$-3.78

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q1 26May 07, 26 | 12:00 AM
Q4 25Feb 26, 26 | 4:30 PM
Q3 25Nov 06, 25 | 4:30 PM

Peer Comparison


TickerCompany
WATWaters Corporation
PHGKoninklijke Philips N.V.
MTDMettler-Toledo International Inc.
IQVIQVIA Holdings Inc.
DGXQuest Diagnostics Incorporated
BNTXBioNTech SE
STESTERIS plc
ILMNIllumina, Inc.
DXCMDexCom, Inc.
TEVATeva Pharmaceutical Industries Limited